NVS
Novartis AG ADR
NYSE: NVS · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$153.07
-0.55% today
Updated 2026-06-12
Market cap
$273.77B
P/E ratio
20.59
P/S ratio
4.84x
EPS (TTM)
$6.97
Dividend yield
3.30%
52W range
$109 – $165
Volume
1.5M
WallStSmart proprietary scores
49
out of 100
Grade: C
Sell
Investment rating
3.3
Growth
D4.5
Quality
C9.0
Profitability
A+3.3
Valuation
D4/9
Piotroski F-Score
Moderate
2.0
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →208 stocks currently score above 75
Price targets
Analyst target
$141.20
-7.75%
12-Month target
$131.02
-14.41%
Intrinsic (DCF)
$91.39
Margin of safety
-62.07%
3 Strong Buy2 Buy5 Hold2 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 23.90% — above average
+ ROE 35.14% — strong efficiency
+ Free cash flow $2.87B — positive
Risks
- Revenue declining -0.70% QoQ
- 62.07% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $43.46B | $46.66B | $51.72B | $54.81B | $56.58B | $59.2B |
| Net income | $6.96B | $14.85B | $11.94B | $14.06B | $3.16B | — |
| EPS | — | — | — | — | $6.97 | $9.85 |
| Free cash flow | $11.56B | $11.71B | $13.80B | $17.69B | $2.87B | — |
| Profit margin | 16.00% | 31.83% | 23.09% | 25.64% | 23.90% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2020-07-14 | NOVARTIS, PHARMA AG | Sale | 7,367,387 | — |
| 2020-07-14 | NOVARTIS, PHARMA AG | Buy | 5,908,089 | — |
| 2020-06-30 | NOVARTIS, BIOVENTURES LTD | Sale | 199,996 | — |
Peer comparison
Smart narrative
Novartis AG ADR trades at $153.07. representing a P/E of 20.59x trailing earnings. Our Smart Value Score of 49/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 1.96, it sits in the grey zone. TTM revenue stands at $56.58B. with profit margins at 23.90%. Our DCF model estimates intrinsic value at $91.39.
Frequently asked questions
What is Novartis AG ADR's stock price?
Novartis AG ADR (NVS) trades at $153.07, on a P/E of 20.6x and a P/S of 4.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Novartis AG ADR overvalued?
Novartis AG ADR carries a Smart Value Score of 49/100 (Grade C), which we rate Sell. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $91.39 against the $153.07 price, so on cash flow terms the market is paying a premium for Novartis AG ADR's growth. The Sell rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Novartis AG ADR (NVS)?
The 12-month analyst consensus target is $141.20, about 7.8% below the current $153.07. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of NVS by 2030?
Our research-backed model puts the 2030 base case at $134.24, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Novartis AG ADR (NVS)?
Our DCF model estimates intrinsic value at $91.39, a -62.1% margin of safety versus today's $153.07. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Novartis AG ADR's revenue?
Novartis AG ADR's trailing twelve-month revenue is $56.58B, and our model projects it reaching about $81.50B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Novartis AG ADR's Altman Z-Score is 1.96, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio4.84x
ROE35.14%
Beta0.49
50D MA$149.41
200D MA$140.84
Shares out1.91B
Float1.81B
Short ratio—
Avg volume1.5M
Performance
1 week+0.00%
1 month+0.20%
3 months-3.30%
YTD+7.62%
1 year—
3 years—
5 years—